Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Sponsor: National Cancer Institute (NCI)
Listed as NCT03220022, this observational or N/A phase trial focuses on AIDS-Related Lymphoma and Ann Arbor Stage II Diffuse Large B-Cell Lymphoma and remains ongoing. Sponsored by National Cancer Institute (NCI), it has been updated 58 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Study Description(click to expand)PRIMARY OBJECTIVES: I. To assess the safety and tolerability of ibrutinib and rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (EPOCH) in participants with acquired immunodeficiency syndrome (AIDS)-related lymphomas (ARL). SECONDARY OBJECTIVES: I. To evaluate the complete response (CR) rates of ARL to ibrutinib and R-da-EPOCH. II. To measure the 1-year and 2-year overall and progression-free survival of participants with ARL treated with combination ibrutinib and R-da-EPOCH, including preliminary comparison of non-germinal center B-cell (GCB) with historical controls treated with R-da-EPOCH. III. To categorize and compare the cell-of-origin by gene expression profiling (GEP) gene expression-based classification (GCB, activated B-cell-like, unclassifiable) to immunohistochemistry (IHC) classification (GCB, non-GCB), estimate the discordant classification, and correlate each biological classification (IHC and GEP) with treatment response rates and survival. IV. To calculate the percentage of participants who receive two or more cycles of R-da-EPOCH, and are able to continue on a minimum dose level of cyclophosphamide of -1 and above after dose adjustments for hematologic toxicities. V. To determine the average number of days per cycle participants are able to stay on planned dose of ibrutinib at the recommended phase II dose (RP2D). VI. To assess the effect of ibrutinib and R-da-EPOCH...
PRIMARY OBJECTIVES:
I. To assess the safety and tolerability of ibrutinib and rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (EPOCH) in participants with acquired immunodeficiency syndrome (AIDS)-related lymphomas (ARL).
SECONDARY OBJECTIVES:
I. To evaluate the complete response (CR) rates of ARL to ibrutinib and R-da-EPOCH.
II. To measure the 1-year and 2-year overall and progression-free survival of participants with ARL treated with combination ibrutinib and R-da-EPOCH, including preliminary comparison of non-germinal center B-cell (GCB) with historical controls treated with R-da-EPOCH.
III. To categorize and compare the cell-of-origin by gene expression profiling (GEP) gene expression-based classification (GCB, activated B-cell-like, unclassifiable) to immunohistochemistry (IHC) classification (GCB, non-GCB), estimate the discordant classification, and correlate each biological classification (IHC and GEP) with treatment response rates and survival.
IV. To calculate the percentage of participants who receive two or more cycles of R-da-EPOCH, and are able to continue on a minimum dose level of cyclophosphamide of -1 and above after dose adjustments for hematologic toxicities.
V. To determine the average number of days per cycle participants are able to stay on planned dose of ibrutinib at the recommended phase II dose (RP2D).
VI. To assess the effect of ibrutinib and R-da-EPOCH on levels of circulating tumor deoxyribonucleic acid (DNA).
VII. To assess the effect and degree of ibrutinib and R-da-EPOCH on T-cell receptor signaling via ITK inhibition.
VIII. To assess the effect of ibrutinib and R-da-EPOCH on B-cell receptor signaling pathway including BTK activity in ARL.
IX. To evaluate the soluble cytokine response to ibrutinib and R-da-EPOCH. X. To characterize the pharmacokinetics of doxorubicin, etoposide, and vincristine in the presence of ibrutinib, and vice versa, and assess the clinical relevance of any drug-drug interaction and correlate with pharmacodynamics outcomes.
OUTLINE: This is a dose escalation study of ibrutinib.
Patients receive rituximab intravenously (IV) on day 1 (for CD20 positive patients only), etoposide IV over 96 hours on days 1-4, doxorubicin hydrochloride IV over 96 hours on days 1-4, vincristine sulfate IV over 96 hours on days 1-4, prednisone orally (PO) daily on days 1-5, cyclophosphamide IV over 1 hour on day 5, and ibrutinib PO once daily (QD) on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim subcutaneously (SC) from 1 calendar day up to 48 hours or filgrastim SC beginning on day 6 for up to 10 days until absolute neutrophil count (ANC) is satisfactory.
After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for up to 5 years.
Status Flow
Change History
58 versions recorded-
Apr 13, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE1 → None
-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
▶ Show 53 earlier versions
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE1
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Apr 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Oct 2021 — Apr 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
Status: Recruiting → Not Yet Recruiting
-
Aug 2020 — Nov 2020 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Jun 2020 — Aug 2020 [monthly]
Suspended PHASE1
-
May 2020 — Jun 2020 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE1
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE1
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE1
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE1
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE1
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE1
-
May 2019 — Jul 2019 [monthly]
Recruiting PHASE1
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE1
-
Dec 2018 — Mar 2019 [monthly]
Recruiting PHASE1
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE1
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2018 — May 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (HIV)-positive stage II-IV diffuse large B-cell lymphomas. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride may work better in treating patients with HIV-positive diffuse large B-cell lymphomas.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .